Overall, this is a well designed and clearly written study with a large, randomly selected population. However, I have the following major concerns:
"impact of LLD use" is not correct. 5-It is not obvious which kind of LLD (statins or other types) has been used during the study period.
6-A thorough evaluation of age-period-cohort (APC) effects is essential for understanding observed longitudinal changes in mean of cholesterol in the cohort population. Authors could present the results in three sections for clarifying the effect of age, period and cohort, separately.
7-The range of age group for Tromso 2 is 20-49 years, however in other surveys the rang is 20-89 years. As the mean of cholesterol depends on the age, lower mean age of the Tromso 2 population compared to other surveys can affect the precise of secular trend of cholesterol.
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GENERAL COMMENTS
This longitudinal analysis of cholesterol trend data in Tromso Study participants will interest readers. The paper is relatively sparse concerning information beyond cholesterol levels, but the information presented is excellent. The authors document trends in cholesterol over the span of decades. The data presentation is generally quite sound. I have a few recommendations for improvement. At this point my overall impression is to accept the paper with minor revisions. The data are presented well and the conclusions are very reasonable. A few changes and clarifications would help to improve the presentation. The paper would be improved if you included a limitations section at the end of the discussion. You could make some statements about not having data or analyzed information related to weight, diet, and other potential mediators of lipid changes. Specific 1. Page 12, conclusion: First sentence is excellent and summarizes your findings. Suggest rewording and put this in your abstract as the conclusion of the abstract on page 2. 2. Table 1 : Consider dropping the final column. You could mention all models were at P<0.0001 except for the men 20-29 years. In place of the p-value column consider inserting the beta coefficient for the change over the study exams #2-#6. 3. Figure 2 . The caption describes 4 lines but it appears that each panel only has 3 lines. Please clarify.
trends in cholesterol levels within a Norwegian population.
Specific comments: 1) Page 3, abbreviation LLD has not been explained 2) Concerning the secular trend analyses, it is very important to take account the attrition issues. Supplementary Tables 3 and 4 are useful, but the issue should be more thoroughly analysed. i) Statistical testing should be performed to evaluate whether there are significant differences between the groups shown in Supplementary  Tables 3 and 4 , ii) As there seem to be substantial differences in some age groups between constant and non-constant participants, these differences should be taken into account while providing "real" secular trend estimates.
3) A very important strength of the current study is the existence of LLD data. However, this data could be utilized better. It would be interesting to see, whether similar estimates compared to present data could be observed if i) utilizing cholesterol data prior and after LLD use, and LLD details (drug name and dose) individual personby-person estimates would be calculated for the probable level of cholesterol decrease due to LLD therapy, ii) another option would be to calculate the person-by-person change in cholesterol percentile between visits before and after the initiation of LLD therapy. Table 1 , it would be useful to have 2 decimal points in cholesterol values. In addition, SD values would be informative.
4)

VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Overall, this is a well designed and clearly written study with a large, randomly selected population. However, I have the following major concerns:
Major concerns:
1-The main weakness of the manuscript is exclusion of 42% of the participants from the study due to having only one blood sample; the remaining population cannot be representative of the original target population.
We have included all blood samples from all participants in the analysis, as described in the section Strengths and limitations of this study: "41% of the participants contributed with only one blood sample." (page 3) (formerly 42%, but after inclusion of data from the latest survey the proportion changed to 41%).
2-In the introduction, the authors state "the aim of study is analysis the impact of LLD use on cholesterol levels in a general population. However, many mediating factors such as physical activity, energy intake, fat intake and BMI may be contributed to the decreased in cholesterol over time. Those additional factors may confound the true association between cholesterol and LLD use over time.
We agree with the reviewer's concern about additional factors that could confound the association. We refer to coinciding trends in physical activity and BMI in the section Discussion under the subheading The impact of lifestyle factors and lipid-lowering drug treatment (page 12-13). Unfortunately, we do not have information about longitudinal changes in energy intake and fat intake, which would be of particular interest, and can only refer to trends presented from data on the national level, as described in the same section (page 12).
3-In the strengths of the study, authors state that they "followed trends in cholesterol, LLD use and associated risk factors"; however, they did not measure any risk factors in the study (page 3, line 5).
We agree with the reviewer's concern about this sentence and have rewritten the sentence to "total cholesterol and lipid-lowering drug use" (page 3).
Specific comments:
4-The title of manuscript is not appropriate and should be corrected. The LLD use was not adjusted for confounders, therefore using the "impact of LLD use" is not correct.
In accordance with the suggestions from the reviewer (and the editorial requirements) we have rewritten the title to "Longitudinal and secular trends in total cholesterol levels and lipid-lowering drug use among Norwegian women and men born 1905-1977 in the population-based Tromsø Study 1979-2016" excluding "the impact of" (page 1). Further, in accordance with this change, we have omitted the use of the same term ("impact of LLD use") in the section Introduction (page 4), and in the section Results in the title of the subheading The use of lipid-lowering drug treatment (page 10).
5-It is not obvious which kind of LLD (statins or other types) has been used during the study period.
We agree with the reviewer that the suggested analyses would add clinically important information. However, such data was not available for this particular project.
We agree with the reviewer, this a major concern for longitudinal analysis, however often very difficult to do for theoretical reasons. We have separated the analyses into secular trends (cholesterol trends in age-groups over time) and longitudinal trends (cholesterol trends in birth cohorts over time). However, the issue presented above, a thorough evaluation of age-period-cohort has not been analysed on our material. The individual contribution of these three factors could not be investigated in our analyses, and we have included the following sentence in the section Discussion under the subheading Longitudinal trends to highlight this: "The unique contribution of age, period and cohort could not be isolated in our analyses." (page 12).
The variation in age groups differed between the surveys from Tromsø 2 (1979-80) to Tromsø 7 (2015-16) , as shown in Table 1 . To avoid the issue stated by the reviewer, all analyses of secular trends have been performed in age groups, as described in the section Methods under the subheading Statistics (page 6-7).
Reviewer: 2 This longitudinal analysis of cholesterol trend data in Tromso Study participants will interest readers. The paper is relatively sparse concerning information beyond cholesterol levels, but the information presented is excellent. The authors document trends in cholesterol over the span of decades. The data presentation is generally quite sound. I have a few recommendations for improvement. At this point my overall impression is to accept the paper with minor revisions.
The data are presented well and the conclusions are very reasonable. A few changes and clarifications would help to improve the presentation.
The paper would be improved if you included a limitations section at the end of the discussion.
In accordance with the journal requirements, the limitation section Strengths and limitations of this study is placed after the abstract (page 3). This section has been revised in accordance with the editorial requirements and the suggestions from the reviewers.
You could make some statements about not having data or analyzed information related to weight, diet, and other potential mediators of lipid changes.
In accordance with the suggestions from the reviewer, we have included the following sentence in the section Strengths and limitations of this study: "Further, a limitation is that data on weight, diet, and other potential mediators of cholesterol changes has not been analysed." (page 3). Specific 1. Page 12, conclusion: First sentence is excellent and summarizes your findings. Suggest rewording and put this in your abstract as the conclusion of the abstract on page 2.
As suggested by the reviewer, we have changed the Conclusion (page 2) in the section Abstract to match the first sentence in the section Conclusion.
2. Table 1 : Consider dropping the final column. You could mention all models were at P<0.0001 except for the men 20-29 years. In place of the p-value column consider inserting the beta coefficient for the change over the study exams #2-#6.
As suggested by the reviewer, we have replaced the p-values with the regression coefficients (estimated per 10 year). We have also added 95% confidence limits for the coefficients (see table 1 ).
3. Figure 2 . The caption describes 4 lines but it appears that each panel only has 3 lines. Please clarify.
There are 4 lines for each panel as descried in the figure legends, however, due to few LLD-users in Tromsø 4 (as described in the Results under the section The use of lipid-lowering drug treatment (page 11) and shown in Table 3 Reviewer: 3 This is an interesting and important paper from a view of cardiovascular epidemiology investigating secular and longitudinal trends in cholesterol levels within a Norwegian population.
Specific comments: 1) Page 3, abbreviation LLD has not been explained
We have rewritten the word omitting the abbreviation in this section Strengths and limitations of the study, so that the word is written in full: "lipid-lowering drug" (page 3).
2) Concerning the secular trend analyses, it is very important to take account the attrition issues.
Supplementary Tables 3 and 4 are useful, but the issue should be more thoroughly analysed. i) Statistical testing should be performed to evaluate whether there are significant differences between the groups shown in Supplementary Tables 3 and 4 , ii) As there seem to be substantial differences in some age groups between constant and non-constant participants, these differences should be taken into account while providing "real" secular trend estimates.
i) As suggested by the reviewer we have tested the difference between the groups in the former Supplementary Tables 3 and 4 (now Supplementary Tables 4 and 5) , and added a footnote for the tests that were significant. ii) To account for missing observations when presenting secular trend estimates we have used linear mixed models to estimate the secular means. The linear mixed models take into account missing observations by assuming that the missing observation are missing at random. We have also used linear mixed models when we estimated longitudinal trends (see Table 1 and the section Statistics (page 8), Figure 3 , Supplementary Figure 1 ).
3) A very important strength of the current study is the existence of LLD data. However, this data could be utilized better. It would be interesting to see, whether similar estimates compared to present data could be observed if i) utilizing cholesterol data prior and after LLD use, and LLD details (drug name and dose) individual person-by-person estimates would be calculated for the probable level of cholesterol decrease due to LLD therapy, ii) another option would be to calculate the person-byperson change in cholesterol percentile between visits before and after the initiation of LLD therapy.
We agree with the reviewer that the suggested analyses would add clinically important information. However, such data is not available in the Tromsø Study. Table 1 , it would be useful to have 2 decimal points in cholesterol values. In addition, SD values would be informative.
4)
We have changed Table 1 as suggested by the reviewer (and reviewer number 4) (see Table 1 ).
Reviewer: 4 This manuscript is timely given the focus on improving cardiovascular health and addresses an important gap in the literature by providing longitudinal data. In general, the statistical methodology utilizing both linear mixed modeling (LMM) and generalized estimating equations (GEE) are appropriate for the data and research question. I have mostly minor concerns and will detail them below. My two more major recommendations are at the end of the document in the summary statement. Abstract 1. Please clarify references to blood cholesterol as total cholesterol, and then abbreviate to TC throughout. This is important particularly as elevated HDL is not of course a risk factor, and that different types of cholesterol have shown different rates of decrease in various studies throughout recent years in various studies.
We have changed the text as suggested by the reviewer and replaced total cholesterol and cholesterol with "TC" throughout the abstract. Further, we have rewritten "cholesterol" to "total cholesterol" throughout the manuscript, with a few exceptions (to avoid repetitiveness).
2. Unrelated to the actual abstract but important later: clarification on why only TC was examined would be important to include. If only this data was available that's fine, but otherwise the authors may wish to differentially examine non-HDL trends. If TC is decreasing because of HDL and not LDL, this is problematic. I don't think this is the case given the other literature, but important statistically to consider.
We agree with the reviewer that this is an important distinction, and have included in the manuscript that we have assessed whether the observed trends in total cholesterol was independent of HDL cholesterol by including the following two sentences in the Method section under Statistics and in the Result section, respectively: "In a separate set of analyses we assessed whether the observed trends in TC was independent of HDL cholesterol by including HDL cholesterol as a covariate in the models" (page 6) and "The regression coefficients for those aged ≥ 30 years presented in table 1, 11 out 12 coefficients were not confounded but HDL as the regression coefficients changed by ≤ 8% when HDL was included in the model." (page 9). Introduction 1. Although I'm primarily providing a statistical review, I wish to note this introduction could be substantially expanded by some of what I mention above. I would also be particularly interested in a discussion about increasing usage of lipid lowering medication in the elderly over time. It seems like there is a better review of literature in the discussion than in the introduction of this topic.
In this study, we have presented the increase in use of lipid-lowering drugs particularly in the elderly. We have shown the longitudinal trend in total cholesterol with increasing age (and time), in the total sample ( Figure 3 ) and in never-users of lipid-lowering drug use (Supplementary Figure 1) . In the discussion, we have referred to other studies also reporting that total cholesterol increase with age and then decrease in older age, which could be explained partly by lipid-lowering drug use (page 11). We have also, in accordance with the comment from Reviewer 1, included a sentence that we could not investigate the individual contribution of the three factors age-period-cohort in our analysis (page 12).
Methods Statistics a. Given the analysis objectives (in the introduction and in results), please enunciate secular versus longitudinal trend analysis within the statistical section.
We have rewritten the section Methods under the subheading Statistics so that secular and longitudinal analysis are separated also in the Statistic section (page 6-8).
b. Given stratification, I am guessing the LMM relates to secular trends? Is the repeated statement on the cohort or on the individual?
Thank you for pointing this out. As a response to this reviewer and reviewer 3 we have re-estimated those total cholesterol trends that initially were presented as calculated arithmetic means in different strata (e.g. sex, age group or birth cohort, survey number). All revised total cholesterol means are now estimated using linear mixed models, both when assessing secular trends in age groups and longitudinal trends in birth cohorts. When assessing secular trends, we use linear mixed models to account for repeated measures (some of the individuals belong to the same age group across two consecutive surveys and we have used LMM to account for this repeated observation). When assessing longitudinal trends within each 10-year birth cohort our participants attend between one and six surveys and we account for these repeated observations by using LMM. Another reason for using LMM is to account for missing observations across the repeated observations. Because we have repeated observations both in the secular models and in the longitudinal models we have the same repeated statement (on individual ID and not on cohort) in both set of analyses. We have rewritten the Statistics section (page 6-8) to make this clearer.
c. With the focus on linear trends, perhaps presenting competing non-linear trends would be important. It looks like the LMM trends slightly decrease, plateau, and then more substantially decrease in the last few cohorts?
We agree that the secular trends are not linear and that a more moderate decrease in total cholesterol were observed between the second and third time point. If we include date of examination as a continuous variable in our secular models and add a second and third degree polynomial term, we observe a significant non-linear effect in all age groups. However, even though trends are not the same between the different time intervals, the general trend is that we observe a decrease from every time point to the next. This is more apparent after we have added an additional time point to our models (the seventh survey (Tromsø 7, 2015-16) ).
Figure 1 clearly indicates this steady decrease in total cholesterol and we do think it is not necessary to add p-values comparing different slopes between the different time points. The power in our study to detect such differences is so high that all noticeable differences would be significant. We have added a sentence in the Result section about the observed plateau between the second and third time point (page 8).
d. Was REML used to deal with the inconsistent time spacing and number of measurements of individuals? (I think this is the default for SAS?)
We did use REML estimation and have added this information to the statistical method section. We have rewritten the Statistics section so that it includes information on how we treated the time variable.
f. Figure 1 -why the stratification at age 50 (seen in figure but not explained in this section)? More information about the estimation method used please.
In Figure 1 which show secular trends over time (survey), we stratified the two age groups (30-49 years and 50-89 years for two reasons 1) because we only have information from age-group 50+ from Tromsø 4 (1994-95) and onwards, and 2) because this stratification fitted the observed data for both sex differences (where women had lower total cholesterol than men before the age of 50 and then had higher levels after the age of 50, as described in the section Results under subheading Secular time trends (page 9) and for lipid-lowering drug use differences (where lipid-lowering drug use was rare before the age of 50), as described in the section Results under subheading The use of lipidlowering drug treatment (page 10). The reason for not having information from all age groups for all surveys were due to different sampling methods at each survey, which is described in the section Strengths and limitations of this study (page 3), and shown in Table 1 . We have rewritten the section Statistics (page 6-8) so that it includes more information about the estimation method.
g. Separate paragraph and clarification needed on estimation of change in TC due to LLD use formula -it says the beta of time in cholesterol was from LMM, but is it being combined with the beta of time in LLD from the GEE? I don't think that's right, I think this was a separate model from the p-values presented in Table 1 and 3. So let's see, using separate LMMs with repeated on cohort (not individual?) with 1) unadjusted time effects chol and 2) adjusted for LDD time effects, which would make that formula make sense if using complete case (ie, same individuals) between the two models. These results are not presented in tabular form, only in paragraph of results page 9?
Thank you for pointing out that the statistical method section needs to be improved with more details about our models. In response, we have rewritten the whole section. Regarding the estimation of change in total cholesterol due to LLD use we did use two LMMs to estimate the betas. Model one included time as a continuous variable adjusted for age, and model 2 included model 1 + a binary variable indicating LLD use (yes/no). The repeated statement in all our models was on individuals and not on cohort, as our participants could have contributed with repeated measures in all our models.
h. Was this then used as the basis for Figure 2 ? Again, I don't think so, so perhaps a different paragraph for this section.
We have not used LMM as a basis for estimation Figure 2 . We have added a separate paragraph for this information (page 7).
i. It seems like Figure 3 is really the "meat" of the paper. After all, we know from the literature about cohort trends of cholesterol and LLD, and what we don't really know about are the longitudinal trends. So, I would recommend putting more emphasis on this section of the analysis plan, and not include information pertaining to this as supplementary but rather as the main focus of the manuscript. I'm pretty confused about how these models were conducted.
We agree with the reviewer that the longitudinal part of the manuscript is quite novel. We believe that both the secular and the longitudinal part of the paper will add new results to the literature regarding total cholesterol trends. We have expanded the longitudinal Result section with some additional analyses which also are described in the section Statistics under the section Methods.
j. Reference to a non-existent supplementary figure 4? Think this is supplemental figure 2?
We apologise for this typographical error and have corrected this in the section Methods under the subheading Statistics (page 8).
Results 1. Given my unfamiliarity with the cohort populace, I would appreciate a demographic characteristic table particularly as I imagine this differs by age and cohort.
As suggested by the reviewer, we have included a table presenting sample characteristics (see Supplementary Table 1) .
2. Was any consideration given to including obesity indicators? I'm curious given the increased prevalence of lipid lowering medication among the elderly and if that is constituent with increases in other chronic conditions as well.
We agree with the reviewer that the suggested analyses would be of clinical interest. However, due to that such an analysis would also have to include other covariates, we consider this as a separate project.
3. More real estate on longitudinal trends please! I think this is really what is new to the literature, and I'm loving figure 3 but want a LOT more information here. What differences exist over time? There's no data beyond the figures, and I think pointing to significant p-values of both time and group here would be really interesting.
We have expanded the longitudinal Result section with some additional analyses which also are described in the section Statistics under the section Methods. We especially assessed trends between 1994 to 2016 and tested for differences between birth cohorts.
4. Reference to a non-existent supplementary figure 4? Think this is supplemental figure 2?
We apologise for this typographical error and have corrected this in the section Results under the subheading The use of lipid-lowering drug treatment (page 10).
5. More generally, would like to see the estimates associated with LMM and GEE models and general model fit characteristics. Reliance on linear p-values is insufficient towards understanding trends over time.
We have revised the statistical method section so that it is clearer how we have performed our statistical analyses. We have also included linear regression coefficients in Table 1 , showing effect size for linear trend in total cholesterol within each age group. We have also estimated trends in the longitudinal models for the period 1994 to 2016 and tested for differences between the birth cohorts
We believe that a presentation of the proportions of LLD use are the main results in Table 3 . GEE was used to test for linear trend over four time points (1994-95, 2001, 2007-08, 2015-16) . Since most tests for linear trends are significant we believe that Table 3 clearly shows that LLD use significantly increase with time for those 40 + years of age. This is even more apparent after we have added the seventh survey (Tromsø 7, 2015-16) as an additional time point. Tables  1. Table 1 : Please include a measure of variability with the point estimate in parentheses rather than the N. I like the inclusion of N, but also feel a measure of spread is necessary with the point estimate.
We have added standard deviations to Table 1 , which now include estimated marginal means with standard deviation and number of observations in parenthesis.
2. Table 1 : Please check first p-value, women 20-29, against non-linear fit.
As a response to reviewer 3 we have added regression coefficients for the linear association with time. However, we acknowledge that although all linear regression coefficients are significant (except men aged 20-29-years) we observe that we have significant non-linear relationships in all age groups. The general trend is that we observe a decrease from every time point to the next (except for 1986-1994) . A more moderate decrease in total cholesterol were observed between the second and third time point. We have added this information to the Results section (page 8).
3. Table 3 : check p-value 30-39 women and 50-59 men against non-linear fit.
The p-values in Table 3 were included primarily to indicate that we have observed a significant increase in LLD use after 1994. We have rerun the GEE models using date of examination as a continuous variable in our models and updated the p-values in the table. Test for the observed nonlinear trends for 30-39-years women and 50-59 men are not performed. We cannot see a reason to suspect a different trend in these two age groups compared to the others. 
Summary
In summary, this was a well-written manuscript and I believe an important contribution to the literature. Under my statistical review, I would recommend:
1. More emphasis on longitudinal analysis throughout. We know the cohort trends based on other studies, but this is one of the first with longitudinal data. This would include reorganizing the longitudinal analysis out of supplemental material and expansion on statistical methods used for the longitudinal analysis.
We have restructured the Statistics section and included more information about our statistical models. We have also expanded the analyses regarding the longitudinal models, as described more in detail after each comment above.
2. Inclusion of model fit and estimates for all models.
In this revision we have fitted more models, both when assessing secular trends and longitudinal trends. For secular trends we have estimated marginal means of cholesterol across the surveys within 10-year age groups. We have also reported regression coefficients for the linear association between time and total cholesterol. For the longitudinal models we have fitted more models for the time period 1994 to 2016. In this period, we have complete data also for those age 50-59 years and older. The trends presented in Figure 3 shows that a linear association between time and total cholesterol could be reasonable fitted within each 10-year birth cohort. We have therefore fitted linear mixed models with the following independent variables: date of survey as a continuous time variable, indicator variables of each 10-year birth cohort, and two-way interaction terms between each birth cohort and time. We also modelled birth cohort as an ordinal variable in separate models. These models gave us the opportunity to estimate and test for different time trends across birth cohorts.
